Your session is about to expire
← Back to Search
Sequential vs Concurrent Chemotherapy with Radiation for Breast Cancer
Study Summary
This trial is testing whether giving partial breast irradiation and chemotherapy at the same time has the same side effects and outcomes as giving partial breast irradiation and chemotherapy at different times.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My oncologist has recommended chemotherapy for me.I have received initial treatment with chemotherapy or hormone therapy for my current cancer.I have been treated with specific chemotherapy regimens before joining.I am 18 years old or older.I had breast cancer on the same side and have been cancer-free for less than 5 years.My breast cancer is either squamous cell or sarcoma.My breast cancer is confirmed to be invasive adenocarcinoma.My surgery removed all visible cancer without leaving any behind.I am fully active and can carry on all my pre-disease activities without restriction.I am not pregnant and will use non-hormonal birth control during treatment.My breast cancer is in an early stage, with a small tumor and few affected lymph nodes.My partial breast irradiation is scheduled within 71 days after my last breast surgery.My cancer is currently active in its original location or nearby.I may receive more cancer treatments as decided by my cancer doctor.I have had a mammogram on both breasts before surgery.
- Group 1: PBI
- Group 2: PBI with chemotherapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this research exclude patients who are octogenarians?
"This trial is open to patients aged 18-100. There are significantly more trials for older age brackets, with 2601 studies conducted on patients over 65 and only 76 focused on those under 18."
Can you name all of the places where this research is being conducted?
"Currently, there are 6 sites across the United States enrolling patients for this clinical trial. They are located in York, Indianapolis, San Antonio and 3 other locations. To limit travel if you choose to enroll, please select the location nearest to you."
Are people with the required conditions still able to join this experiment?
"That is right, the clinicaltrials.gov website indicates that this trial is actively seeking patients. The listing was created on September 1st 2013 and updated most recently on August 25th, 2020. There are 159 total spots available at 6 different hospitals or research centres."
Is this study open to every patient or are specific inclusion criteria necessary?
"This study is recruiting 159 participants with breast cancer. Inclusion Criteria: Age ≥ 18 years. Patient must have histologically confirmed (by routine H&E staining) invasive adenocarcinoma of the breast. Primary tumor ≤ 4cm and 0-3 positive axillary lymph nodes (T1-2, N0-1, M0). Margin negative surgery. For subjects with two breasts, they must have had a bilateral mammogram prior to surgery. Patient must have a Medical Oncology consult with the recommendation of chemotherapy. Recommended regimens are as follows: Cyclophosphamide and Dox"
How many people are subjects in this experiment?
"That is correct. The online clinicaltrials.gov database shows that this research is currently looking for participants. This study was first advertised on September 1st, 2013 and the details were last updated on August 25th, 2022. They are hoping to enroll 159 individuals at 6 sites total."
Share this study with friends
Copy Link
Messenger